Psychemedics Corp.  

(Public, NASDAQ:PMD)   Watch this stock  
Find more results for PMD
11.12
+0.69 (6.62%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.19 - 11.24
52 week 7.76 - 17.83
Open 10.76
Vol / Avg. 16,733.00/22,402.00
Mkt cap 58.18M
P/E 30.02
Div/yield 0.15/5.40
EPS 0.37
Shares 5.42M
Beta 1.19
Inst. own 61%
Apr 25, 2016
Q1 2016 Psychemedics Corp Earnings Release (Estimated) Add to calendar
Feb 10, 2016
Q4 2015 Psychemedics Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 11.24% 10.98%
Operating margin 7.78% 16.06%
EBITD margin - 19.65%
Return on average assets 13.86% 15.78%
Return on average equity 26.35% 25.53%
Employees 156 -
CDP Score - -

Address

125 Nagog Park Ste 200
ACTON, MA 01720-3451
United States - Map
+1-800-6288073 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Psychemedics Corporation (Psychemedics) provides testing services for the detection of drugs of abuse through the analysis of hair samples. The Company’s testing methods utilize a technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company’s primary application of its technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse. The Company performs a custom-designed enzyme immunoassay (EIA) on the liquid supernatant, with confirmation testing by mass spectrometry. Psychemedics provides screening and confirmation by mass spectrometry using various practices for cocaine, marijuana, phencyclidine (PCP), amphetamines, including ecstasy, and opiates, including heroin, hydrocodone, hydromorphone, oxycodone and codeine. The Company also offers a test for alcohol using hair, which measures average alcohol consumption over a period of approximately three months.

Officers and directors

Raymond C Kubacki Jr. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Neil L. Lerner Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Michael I. Schaffer Ph.D. Vice President - Laboratory Operations
Age: 70
Bio & Compensation  - Reuters
James V. Dyke Corporate Vice President - Sales and Marketing
Age: 50
Bio & Compensation  - Reuters
A. Clinton Allen Independent Director
Age: 71
Bio & Compensation  - Reuters
Harry F. Connick Sr. Independent Director
Age: 89
Bio & Compensation  - Reuters
Walter S. Tomenson Jr. Independent Director
Age: 68
Bio & Compensation  - Reuters
Fred J. Weinert Independent Director
Age: 67
Bio & Compensation  - Reuters